Ozmosi | Asapiprant Drug Profile

Product Description

asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26277322/)

Mechanisms of Action: PGD2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shionogi
Company Location: Asia Pacific
Company Founding Year: 1878
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Rhinitis, Allergic, Perennial|Rhinitis, Allergic, Seasonal

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04705597	BGE-175-201	P2	Terminated	COVID-19	2022-04-20	72%	2023-03-24
NCT01651871	1210D1526	P2	Completed	Nasal Obstruction\|Sneezing\|Rhinitis, Allergic, Seasonal	2012-11-01		2025-08-27	Primary Endpoints\|Treatments
2008-006788-35	2008-006788-35	P2	Completed	Rhinitis, Allergic	2009-07-17		2022-03-13	Treatments
2008-006787-11	2008-006787-11	P2	Completed	Rhinitis, Allergic	2009-05-30		2022-03-13	Treatments
JapicCTI-101361	JapicCTI-101361	P2	Completed	Rhinitis, Allergic, Seasonal	None
JapicCTI-111698	JapicCTI-111698	P2	Completed	Rhinitis, Allergic, Seasonal	None
JapicCTI-121981	JapicCTI-121981	P2	Completed	Rhinitis, Allergic, Seasonal	None
JapicCTI-090875	JapicCTI-090875	P2	Completed	Rhinitis, Allergic, Perennial	None
JapicCTI-132222	JapicCTI-132222	P3	Completed	Rhinitis, Allergic, Perennial	None
JapicCTI-132046	JapicCTI-132046	P3	Completed	Rhinitis, Allergic, Seasonal	None

Recent News Events

Date	Type	Title
05/07/2024	PubMed	The prostaglandin D2 antagonist asapiprant ameliorates clinical severity in young hosts infected with invasive Streptococcus pneumoniae.
05/01/2022	PubMed	Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.
01/26/2022	PubMed	Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9.
08/19/2021	News Article	BioAge Appoints Rekha Hemrajani and Jason Coloma to its Board of Directors
04/14/2021	News Article	BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen's Phase 1 APJ Agonist To Treat Diseases of Aging
04/05/2021	News Article	HitGen and BioAge Announce Research Progress in DNA-Encoded Library Based Drug Discovery Research Collaboration
03/22/2021	News Article	BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging, a Key Cause of Morbidity and Mortality in Older Patients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Asapiprant

Alternative Names: asapiprant, bge-175, bge 175, bge175, S-555739, S555739, S 555739 Clinical Status: Inactive Latest Update: 2024-05-07 Latest Update Note: PubMed Publication